Like I said previously when we received the announcement on 2 October, I have put my faith in Dr Krause, Dr Itescu and Dr Rose ... this long term data was obviously a key component to the BLA resubmission and that is what they were waiting for
In the interim they also submitted substantial new information for the IND back then as per the advice from the FDA through their "active dialog" and reiterated to the market that Remestemcel-L has both a Fast Track designation and a Priority Review, which indicates the data submitted 6 weeks ago is probably already being reviewed .... again I think the 3 amigos mentioned above know what they are doing as opposed to the anonymous posters on here
![]()
The long term data released this morning is extraordinary ... let's hope the FDA draw the same conclusion ?
GLTAH
- Forums
- ASX - By Stock
- MSB
- Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-9
-
- There are more pages in this discussion • 347 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
99.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.130B |
Open | High | Low | Value | Volume |
99.5¢ | $1.00 | 98.5¢ | $375.1K | 379.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 38253 | 98.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 16476 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 71450 | 0.990 |
9 | 51468 | 0.985 |
14 | 134006 | 0.980 |
7 | 86900 | 0.975 |
7 | 216329 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 23713 | 5 |
1.000 | 37662 | 4 |
1.005 | 44235 | 5 |
1.015 | 44800 | 2 |
1.020 | 40967 | 2 |
Last trade - 10.21am 15/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online